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Invasive cervical cancer (ICC) is the third most frequent cancer among women worldwide and is associ-
ated with persistent infection by carcinogenic human papillomaviruses (HPVs). The combination of large
populations of viral progeny and decades of sustained infection may allow for the generation of
intra-patient diversity, in spite of the assumedly low mutation rates of PVs. While the natural history
of chronic HPVs infections has been comprehensively described, within-host viral diversity remains lar-
gely unexplored.
In this study we have applied next generation sequencing to the analysis of intra-host genetic diversity
in ten ICC and one condyloma cases associated to single HPV16 infection. We retrieved from all cases near
full-length genomic sequences.
All samples analyzed contained polymorphic sites, ranging from 3 to 125 polymorphic positions per
genome, and the median probability of a viral genome picked at random to be identical to the consensus
sequence in the lesion was only 40%. We have also identiﬁed two independent putative duplication
events in two samples, spanning the L2 and the L1 gene, respectively. Finally, we have identiﬁed with
good support a chimera of human and viral DNA.
We propose that viral diversity generated during HPVs chronic infection may be fueled by innate and
adaptive immune pressures. Further research will be needed to understand the dynamics of viral DNA
variability, differentially in benign and malignant lesions, as well as in tissues with differential intensity
of immune surveillance. Finally, the impact of intralesion viral diversity on the long-term oncogenic
potential may deserve closer attention.
 2015 Elsevier B.V. All rights reserved.1. Introduction
Papillomaviruses (PVs) are a family of small non-enveloped
viruses, with a circular double-stranded DNA genome, that infect
epithelia in a wide range of vertebrates and probably all amniotes(Bravo et al., 2010). Human PVs (HPVs) are the most studied mem-
bers in the family, because of their medical importance. They are
related to benign proliferative disorders, such as skin warts, epi-
dermodysplasias or condylomata acuminata, and also to malignant
neoplasms of the cervix, anus, vagina, vulva, penis and oropharynx
(Cubie, 2013). To date, more than 180 HPV types have been fully
sequenced (http://pave.niaid.nih.gov/). HPVs are not monophyletic
and belong instead into ﬁve genera, with different types showing
differential association with different diseases (Bernard et al.,
2010; Bravo et al., 2010; de Villiers, 2013).
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2000), but 13 HPV genotypes are classiﬁed by the International
Agency for Research on Cancer as oncogenic: HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59 and 66 (Bouvard et al., 2009).
Carcinogenic potential is not evenly distributed among HPVs, and
HPV16 alone is responsible for more than 50% of the invasive cer-
vical cancer (ICC) cases worldwide (de Sanjose et al., 2010; Li et al.,
2011), and is the most prevalent HPV in other squamous carcino-
mas associated to HPVs infections (De Vuyst et al., 2009; de
Sanjose et al., 2014), as well as in women with normal cytology
(Bruni et al., 2010). In South-East Brazil, 2.3% of women on the
screening population were positive for HPV16 (Levi et al., 2014),
whereas 75% of the ICC cases from the same region were associated
with this HPV (de Oliveira et al., 2013). Genetic diversity among
HPV16 isolates can reach 2%, and the trend is towards
full-genome sequencing of the isolates (Chen et al., 2005, 2009,
2013; Smith et al., 2011).
For rapidly evolving viruses such as HCV or HIV, a wealth of
data has been generated during follow-up studies to address the
question of the amount and generation pace of intra-host genetic
diversity. For PVs infections, however, the common view about
these viruses has precluded experimental research about mutation
and evolutionary rates. Most studies have addressed changes in the
most prevalent, ‘‘consensus’’, sequence during chronic PVs infec-
tions based on Sanger sequencing. This technology may however
not be appropriate to capture the dynamics of slowly evolving
viruses, such as PVs. Very few reports have applied deep sequenc-
ing technologies to gain insight into the accumulation of genetic
diversity during the course of a PV infection. To help bridging this
gap, the aim of the present study is to analyze by means of
next-generation sequencing a number of ICC cases associated to
HPV16 single infections.2. Materials and methods
2.1. Clinical specimens and total DNA extraction
Ten invasive cervical cancers containing HPV16 DNA as single
infection, determined after Linear Array HPV Genotyping (Roche
Molecular Diagnostics, Pleasanton, USA) or PapilloCheck (Greiner
Bio-One GmbH, Frickenhausen, Germany) tests were selected for
the present study. The ICC cases originated from women partici-
pating in a previous study (de Oliveira et al., 2013), and the condy-
loma originated from a women attended at the Gynecological
Department from Hospital das Clínicas – Universidade de São
Paulo. The study was approved by the Brazilian National
Research Ethical Committee (CONEP n158.490).
Total DNA was extracted from fresh tissue using QIAamp DNA
Mini Kit (Qiagen, Gaithersburg, USA) or NucleoSpin Tissue kit
(Macherey–Nagel GmbH&Co, Germany), according to manufac-
turer’s instructions.2.2. HPV16 E6 and E2 real time PCR
To determine the HPV16 physical status a multiplex real-time
PCR for simultaneous detection of the E6 and E2 regions were used.
Primers and probes were modiﬁed from (Canadas et al., 2010), as
follows: primer E6F 50ACCGGTTAGTATAAAAGCAGACATTTTMT30,
primer E6R 50GCTCCTGTGGGTCCTGRAAC30, probe E6 CAL Fluor
Orange 560 BHQplus – CACCAAAAGAGAACTGCAA – BHQ1, primer
E2F 50GCRACGAAGTATCCTCTSCTGAA30, primer E2R 50AAGGCGAC
GGCTTTGGKAT30 and probe E2 FAM – TAYTAGGCAGCACTTGGCCA
ACCA – BHQ1. Real-time PCR was performed in a ﬁnal volume of
25 lL, containing 5 lL of DNA, 1x qPCR Low Mg2+ (Next
Generation ECO HotStart qPCR kit), 200 nM of each primer andprobe. PCR was carried out according to the protocol: for 95 C
for 2 min, 45 cycles of 95 C for 15 s, 43 C for 30 s 60 C for 45 s,
in a 7500 FAST Real Time Systems (Applied Biosystems). In each
run, water was included as negative control, an HPV16 complete
genome plasmid as episomal control, and SiHa DNA as HPV16
DNA integrated control. Physical state was determined by compar-
ing the CtE6/CtE2 ratio of each sample with the ratio observed in
the plasmid control. Samples negative for E2 region were consid-
ered as integrated, samples with the same CtE6/CtE2 ratio of the
plasmid as pure episomal form and samples with a CtE6/CtE2 ratio
lower than the plasmid as mixed (both forms episomal and
integrated).
2.3. HPV16-speciﬁc long PCR
PCR was performed in 50 lL consisting of 1x long PCR buffer
(Fermentas GmbH&Co, Germany), 1.5 mM MgCl2, 0.2 mM of each
dNTP, 0.2 lM of each primer, 1.25 U of long PCR enzyme mix
(Fermentas GmbH&Co, Germany) and 100–300 ng of template
DNA, generating an amplicon of 7935pb. The primers used
(forward-21 50AAACTAAGGGCGTAACCGA30 and reverse-7862 50C
GGTTTGCACACACCCATGT30) were previously described (Sun
et al., 2012). Positions corresponding to 50-end nucleotide of pri-
mers in the HPV16 reference K02718 were annotated following
primer orientation.
PCR cycling conditions were: 94 C for 2 min, 10 cycles of (95 C
for 15 s, 60 C for 30 s and 68 C for 7 min), followed by 25 cycles of
(95 C for 15 s, 60 C for 30 s and 68 C for 7 min with an increment
of 5 s by cycle), plus a ﬁnal extension of 68 C for 10 min.
Long PCR products were separated by electrophoresis and the
approximately 8Kbp band was puriﬁed using Invisorb Fragment
Clean Up (Invitek, Berlin, Germany), according to manufacturer’s
instructions. The puriﬁed PCR product was then submitted to deep
sequencing on the Ion Torrent platform (Life technologies, CA, USA).
2.4. Deep sequencing
Libraries were generated using 100 ng of the long PCR product
and the Ion Shear™ fragmentation method (Life technologies, CA,
USA). Adapters with barcode allowing for multiplexing were
ligated and puriﬁed using the E-Gel SizeSelected™ system (Life
technologies, CA, USA). Samples were quantiﬁed using Ion
Library Quantiﬁcation Kit (Life technologies, CA, USA) and 1–5
libraries from different samples were multiplexed. Samples were
submitted to emulsion PCR using the Ion PGM™ Template 200
kit (Life technologies, CA, USA) and ﬁnally to sequencing reaction
using Ion PGM™ 200 Sequencing kit (Life technologies, CA, USA).
Sequencing was performed in the Ion 314™ chip (Life technologies,
CA, USA) according to the manufacturer’s instructions.
2.5. Deep sequence data analyses
Fastq ﬁles were extracted from the Ion Torrent SFF ﬁles, clipped
and submitted to quality control analyses using FastQC High
Throughput Sequence QC Report software v0.10.1 (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/), for trimming
according to phred scores. Reads were mapped against the
HPV16 reference sequence K02718 using the TMAP v0.2.3 soft-
ware. The mapping results were visualized with IGV viewer
(Thorvaldsdottir et al., 2013). Consensus fasta sequences were gen-
erated using SAMtools v0.1.19 (Li et al., 2009).
2.6. Read depth analysis
A slide-window analysis was performed to verify differences in
the read depth coverage between and/or within the samples, using
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erage value for each window was determined for each sample, and
normalized by the overall median sample coverage.
2.7. Phylogenetic analysis
Fasta consensus sequences obtained from deep sequencing and
a group of 20 HPV16 complete genome sequences retrieved from
GenBank were aligned with Muscle (Edgar, 2004) and edited with
Se-Al v2.0a11 (available at http://tree.bio.ed.ac.uk/software/sea/).
Phylogenetic reconstructions were performed by maximum likeli-
hood (ML) criterion using RAxML version 7.4.8 (Stamatakis et al.,
2005). The best ﬁt model for the ML reconstructions were deﬁned
comparing the Akaike Information Criterion (AIC). For the nucleo-
tide sequences we tested the GTR + C model without partitions,
with one partition per gene and with three partitions per gene.
The preferred model was GTR +C without partitions, which was
used to infer a ML tree. Node support was evaluated using 5000
bootstraps cycles.
2.8. De novo assembly
Regarding intra-host analysis, the reads generated by the Ion
Torrent were submitted to de novo assembly using the CLC geno-
mics workbench software (Qiagen, Gaithersburg, USA). All contigs
obtained were submitted to Blast (http://www.ncbi.nlm.nih.gov/)
to verify whether it was HPV16 or human DNA. Variant calling
was also performed using CLC genomics workbench software
(Qiagen, Gaithersburg, USA) setting the quality phred to 30, mini-
mum coverage 50, minimum frequency to call a SNP of 1% and at
least two reads showing the SNP. The deﬁnition of the threshold
value was based on DNA polymerases proofreading activity, the
deep sequence protocol substitution error rate and in a previous
report (Kukimoto et al., 2013). The enzyme mix used for the long
PCR is a unique blend of two thermostable high ﬁdelity DNA poly-
merases with proofreading activity. The two enzymes generate
long PCR product with three times higher ﬁdelity compared to
Taq DNA polymerase, according to the manufacturer. The deep
sequencing approach used in the present study has a substitution
error rate estimated in 0.07% (Bragg et al., 2013). Besides that, a
previous report by Kukimoto and colleagues analyzing HPV16 epi-
somes present in W12 cells and determining a threshold value of
0.5% (Kukimoto et al., 2013). For the present analysis, we decided
to be more stringent and used 1%. Finally, the presence of SNPs
and indels obtained by the analysis were veriﬁed by visual inspec-
tion of the mapped reads.
2.9. GenBank accession number
KP212150–KP212159 and KP874716.
3. Results
3.1. HPV16 physical status
Based on the E6/E2 real time PCR results, we observed both
forms of the HPV16 genome, episomal and integrated, in six ICC
samples. In the remaining four ICC samples, as well as in the
condyloma, we observed exclusively episomal forms (Table 1).
3.2. HPV16-speciﬁc long PCR
Using an HPV16-speciﬁc long PCR protocol we generated an
amplicon of ca. 8 Kbp from ten clinical ICC samples. In addition
to the expected ca 8 Kbp band, both larger (that were retained inwell of the agarose gel) and shorter amplicons were also produced.
From one of the samples, these additional bands were individually
excised from the agarose gel, puriﬁed and submitted to another
HPV16-speciﬁc PCR targeting the E7 ORF (Walboomers and
Meijer, 1997) that conﬁrmed all bands originated from HPV16 gen-
ome (data not shown).
3.3. Resequencing
Our HPV16-speciﬁc long PCR was able to amplify 7817 bp of
HPV16 genome for all samples from position 37 to 7853 of the
HPV16 reference genome, therefore missing to amplify 89 bp from
the LCR region. HPV16 near full-length and the internal genetic
variation from eleven clinical samples were determined using Ion
Torrent deep sequencing by assembly and comparison against
the HPV16 reference sequence K02718. For each sample, the
assembly algorithm obtained only one contiguous sequence. The
sequence length of the assembled sequences ranged from 7832
to 7901. Table 1 shows the results of this analysis.
The maximum likelihood phylogenetic tree recovered with high
branch support, the four major clades representing the HPV16 vari-
ants and sub-lineages: A (European and E(As)), B (African-1), C
(African-2) and D (North America and Asian-American 1 and 2),
as previous reported (Chen et al., 2005; Burk et al., 2013),
(Fig. 1). Among the eleven samples analyzed, six were classiﬁed
as HPV16_A1, one as HPV16_A2 and four as HPV16_D3. It was
observed a correlation between HPV16 variant and tumor histolog-
ical type (p = 0.047), with squamous cell carcinomas being prefer-
entially associated to HPV16_A, whereas adenocarcinoma cases
were preferentially associated to HPV16_D.
Concerning the ICC samples, pairwise distance of nucleotide
sequences showed high degree of conservation, with the maximum
distance being 0.018. The overall mean genetic diversity was 0.01
for nucleotide sequence. Comparing to the HPV16 reference
sequence changes in 190 (2.4%) nucleotide sites were observed.
At the amino acid level, changes in 67 (2.8%) sites were observed:
the E2 gene showed the highest proportion of amino acid changes
(5.5%), followed by E5 (4.8%), whereas L1 displayed the lowest
(1.7%).
Read depth analysis showed an increase in sequencing coverage
in the region spanning the L1 gene of one sample (CNA20), and in
the L2 region for another one (CNA55). These ﬁndings are compat-
ible with a duplication event (Fig. 2).
3.4. Intra-host HPV16 genetic variability
In order to analyze the intra-host genetic variation, we per-
formed a de novo assembly without a reference sequence, instead
of using any HPV16 genome as scaffold for the assembly of the
gained reads. This assembly generated only one contiguous
sequence for four of the samples (NBM19, CNA15, CNA34 and
CNA138), which were conﬁrmed as being only HPV16.
Assemblies for the remaining seven samples generated three to
eight contiguous sequences, ranging from 553 to 8164 bp in
length; some of them correspond to HPV16 and some to human
DNA. Samples showing more than one contiguous sequence corre-
sponding to HPV16 were analyzed and in all cases only one HPV16
lineage was observed in each sample. Findings of multiple contigs
were thus an artifact of the assembly algorithms. Interestingly, in
one sample (CNA20) one out of six contiguous sequences con-
tained a mixture of HPV16 and human genome, compatible with
a chimeric fragment containing both viral and cellular DNA. This
contiguous sequence, with 671 bp length, was generated by the
assembly of 3186 reads, with an average coverage of 435 is there-
fore extremely unlikely to be an artifact. The ﬁrst breakpoint was
covered by 220 reads and the second breakpoint by 430 reads.
Table 1
Clinical characteristics, HPV16 physical status and resequencing mapping characteristics of near full-length HPV16 genome sequences from deep sequencing.
Sample
ID
Histology FIGO
stage
Age at
diagnosis
HPV16
physical
status
Sequence
length
Number of
reads
Assembled
reads
Mean
coverage/
nt
HPV16 sub
lineage
Diversity
index
GenBank
accession
number
CNA15 SCC IV 40 Episomal 7850 49061 94.7% 660.7 A1 0.393 KP212150
CNA20 SCC IB 32 Mixed 7901 210773 76.4% 2079.7 A1 0.513 KP212151
CNA33 SCC IB 47 Mixed 7901 89247 79.5% 979.8 A1 0.091 KP212152
CNA34 SCC IB 73 Mixed 7888 87408 94.5% 1127.1 A1 0.791 KP212153
CNA55 ADC IIB 53 Mixed 7854 15940 94.8% 191.0 D3 0.741 KP212154
CNA131 SCC IIIA 58 Episomal 7857 29450 94.4% 351.8 A2 0.175 KP212155
CNA137 ADC IB 42 Mixed 7900 258065 79% 2832.0 D3 0.0000791 KP212156
CNA138 ADC IB 40 Mixed 7893 176520 98.3% 2494.7 A1 0.890 KP212157
CNA173 ADC IB 32 Episomal 7832 22923 88.3% 253.1 D3 0.473 KP212158
CNA188 ADC Unk 32 Episomal 7876 44136 89.3% 525.4 D3 0.181 KP212159
NBM19 Condyloma – Unk Episomal 7877 38800 89.3% 600.0 A1 0.387 KP874716
ADC, adenocarcinoma; SCC, squamous cell carcinoma; mixed, both forms episomal and integrated; Unk, unknown.
Fig. 1. HPV16 complete genome unrooted maximum likelihood phylogenetic tree inferred with the study samples (bold) and the HPV16 genome references using GTR + 4C
nucleotide substitution model. Support after 1000 bootstrap cycles is shown for each node. The phylogenetic tree recovered with high branch support, the four major clades
representing the HPV16 variants and sub-lineages.
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tides from 18 to 609 to a 17q12 region of human genome and
the last 69 nucleotides correspond to HPV16 E2 region.
Concerning the variant calling analysis, all SNPs or indels
mapped to homopolymer regions (three or more repetitions) were
disregarded, as homopolymer stretches can induce erroneous base
calls on the Ion Torrent platform. All samples contained polymor-
phic sites, albeit with different degrees (Fig. 3). Sample CNA138
showed the lowest degree of variability, with only three polymor-
phic sites (0.04% of the total positions sequenced), and only one of
them representing more than 5% of the reads in that position.
Conversely, sample CNA137 showed the highest degree ofintra-host variability, with 125 polymorphic sites (1.6% of the total
positions sequenced), and 31 of them representing more than 10%
of the reads in that position.
Samples showed polymorphic sites in all viral genomic regions
(Figs. S1–S9), with exception of CNA138, which harbored polymor-
phisms only in E1 and L2 regions. No speciﬁc proﬁle of mutations
was identiﬁed. However, four samples concentrated almost 40% of
polymorphisms in certain positions: CNA33 showed an admixed
population in the E1 region (positions 903, 1086 and 1113),
CNA131 (position 4157) and CNA188 (position 4182) in the
non-coding region between E5 and L2 genes, and CNA137 in the
L2 region (position 4597) and LCR (position 7796).
Fig. 2. Slide-window analysis, window size 100 bp and step 20 bp, of the read
depth of ten invasive cervical cancer cases and one condyloma. The median
coverage value for each window was determined for each sample, and normalized
by the overall median sample coverage. Read depth analysis shows an increase in
sequencing coverage in the region spanning the L1 gene of one sample (CNA20), and
in the L2 region for another one (CNA55).
Fig. 3. Representation of intra-host HPV16 genetic variability from two invasive
cervical cancer cases. The near full-length HPV16 genomes from clinical samples
were aligned to their de novo assembled genome, and mutation frequency at each
nucleotide position is presented. The red line indicates the threshold value of 1%.
Sample CNA138 showed the lowest degree of variability, with only three
polymorphic sites and sample CNA137 showed the highest degree of intra-host
variability, with 125 polymorphic sites. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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bility of a randomly chosen genome to be identical to the consen-
sus genome, assuming complete independence between sites
(Table 1). The median value of this diversity index for our samples
was 0.39, ranging between 7.9e-4 and 0.89. No correlation was
observed between the diversity index and the age at diagnosis
(p = 0.267), FIGO stage (p = 0.304), tumor histological type, i.e.
squamous vs adenocarcinoma (p = 0.841) or HPV16 physical status,
i.e. integrated vs mixed forms (p = 0.429).4. Discussion
In the present study, we have analyzed HPV16 near full-length
genome from eleven clinical samples (ten ICC cases and one condy-
loma) using an HPV16-speciﬁc long PCR method followed by Ion
Torrent next generation sequencing, a technology able to generate
three–four orders of magnitude more information than Sanger
sequencing technology (Liu et al., 2012). This information density
provided by the deep sequencing approach is fundamental for
the study of viral diversity, as it allows the simultaneous detection
of minor variants. The resolution power makes these techniques
the current standard tool for intra-host viral diversity analyses.
This technology did not allow recovering long-distance haplotypes,
and therefore we cannot estimate a number of potential coexisting
viral variants present in the same sample. Nonetheless, we were
able to approximate the total amount of diversity among the viral
genomes present in each lesion by combining the information
about the individual frequencies of each single nucleotide poly-
morphism identiﬁed, under the assumption of independence
between sites.
Seven out of eleven HPV16 sequences from cervical samples
analyzed in the present study were classiﬁed as variant A. This
variant distribution is in agreement with previous Brazilian stud-
ies, which observed that 34% (Gheit et al., 2006) to 65.8% (Freitas
et al., 2014) of the HPV16 isolates are classiﬁed as HPV16_A vari-
ant. We could ascribe the SNPs in the different isolates here
sequenced to the differential variant signatures (Smith et al.,
2011).
Viral genomes in the HPV infected cells in the mucosal epithe-
lial basal layer remain essentially episomal. During a productive
infection, such episomal forms constitute also the viral genomes
packed into virions and released with keratinocyte shedding
(Doorbar, 2006). However, progression of the malignisation pro-
cess often concurs with integration of viral sequences into the cel-
lular genome as well as with loss of the episomal forms
(Wentzensen et al., 2004; Xu et al., 2013). Thus, preneoplastic
lesions as well as invasive carcinomas usually contain both episo-
mal and integrated HPV genomes, and a fraction (20–40%) of ICC
harbors exclusively integrated viral genomes (Canadas et al.,
2010; Aromseree et al., 2014). In our samples, 45% of the ICC cases
were identiﬁed to harbor HPV16 genomes exclusively in the episo-
mal form. The E6/E2 real time PCR used to assess the HPV physical
status is based on the differential detection of the E6 and E2 genes
(Canadas et al., 2010; Valmary-Degano et al., 2013), since HPV16
integration often entails the deletion of the E2 gene, as observed
in SiHa cells. In certain cases, however, the target region excised
and lost during the HPV integration process does not span the E2
gene (Wang et al., 2013; Akagi et al., 2014). Therefore, we cannot
exclude the possibility that some of the samples identiﬁed to
exclusively carry episomal HPV16 genomes could also contain
integrated forms, as long as the integration has not resulted in
the loss of the E2 gene. Indeed, our results show that we are able
to identify non-standard integration events. One of the contiguous
sequences obtained from the sample containing L1 duplication,
displayed a fragment of human DNA sequence ﬂanked by viral L1
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where in the late region (50 breakpoint) and E1–E2–E5 region (30
breakpoint) (Dall et al., 2008; Xu et al., 2013). Integration sites of
HPV16 in cervical intraepithelial neoplasia are more frequent in
the L1 gene followed by E1 gene (Wang et al., 2013); in ICC samples
although HPV breakpoints are reported preferentially in the viral
E2 gene, high resolution method showed that viral breakpoints
are distributed across the viral genome (Akagi et al., 2014). Our
interpretation is that this contiguous sequence could represent
integrated viruses that we were able to detect. The integration site
was in the 17q12 within the IRZF3 gene that can participate in the
regulation of apoptotic process and Bcl-2 expression (Rebollo et al.,
2001).
One of the main ﬁndings of our study is that intralesion papil-
lomavirus diversity can be high, showing globally that the median
probability of a viral genome picked at random to be identical to
the consensus sequence amounted to barely 40%. Such accumula-
tion of diversity Intra-host HPV genetic diversity is poorly studied,
but deserves more attention, as it could be a hidden factor con-
tributing to different outcomes after infections by the same HPV
type. It is commonly assumed that PVs evolve slowly because they
use the high-ﬁdelity cellular polymerases during replication
(Doorbar et al., 2012). However, the human genome encodes for
several DNA polymerases, differing largely on ﬁdelity and sub-
strate preferences (Loeb and Monnat, 2008). It is not clear which
cellular enzyme/s replicate the viral DNA, and it is also not known
whether the shift in replication mechanics of PVs mentioned above
concurs with a shift in the cellular enzyme(s) in charge of viral
replication. Our results show that viral intralesion diversity levels
did not differ between samples carrying exclusively episomal viral
genomes and samples carrying both episomal and integrated
forms. The contribution of the integration event in viral diversity
accumulation may therefore be minor. Next-generation sequenc-
ing data for cell-culture conditions have shown that HPV16 epi-
somes present in the W12 cell line did not accumulate sequence
variation above 0.5% (Kukimoto et al., 2013). However, using real
clinical samples the same authors reported that above 40% of the
clinical samples contained polymorphic sites reaching frequencies
up to 5%, thus suggesting the potential for intra-host generation of
diversity (Kukimoto et al., 2013). In our study, we have further
detected polymorphic sites in all samples submitted to deep
sequencing, with values for the less prevalent alleles amounting
above 40%. Thus, viral genomic diversity accumulating during the
course of a natural infection contrasts sharply with the absence
of variation generated during in vitro subculture of the W12
episome-containing cells.
Our long PCR is able to detect both HPV16 in episomal form,
as well as the HPV16 DNA integrated into the human genome,
provided there is more than one copy of the virus integrated.
Besides the anticipated near full-length genome, the long PCR
generated additional, smaller and larger amplicons that we con-
ﬁrmed to originate from HPV16. Generation of multiple ampli-
cons using HPV16-speciﬁc long PCR has been described in
previous studies (Kukimoto et al., 2013). Although we cannot
exclude the possibility of these bands to be an artifact of the long
PCR, the replication mechanics of PV genome may also allow for
the generation of such incomplete genomes. PV replication occurs
bidirectionally generating episomes in the early stages of the
infection, and switches to rolling circle mode during the produc-
tive stages of the infection yielding concatemers, in a process
that requires homologous recombination (Flores and Lambert,
1997; Orav et al., 2013). It is unclear how genomic concatemers
are excised and circularized, and viral genomes carrying deletions
and/or insertions may be generated as defective by products,
together with the intact full-length circular genomes (Bravo and
Felez-Sanchez, 2015). On the one hand, we did not observe anydeletion event in any of the samples analyzed, even in the sam-
ples known to contain integrated viral genomes, and similar ﬁnd-
ings have been reported in other laboratories (Kukimoto et al.,
2013). On the other hand, two of our ICC samples showed a sig-
niﬁcant increase in read depth close to L1 and L2, respectively,
compatible with a duplication event of a genome fragment span-
ning these regions. Similar results of partial duplications of the
viral genome have been reported, independently, by different lab-
oratories: analyses of three independent cases of cancer devel-
oped after a long period of recurrent respiratory papillomatosis
associated to HPV6 or HPV11, reported duplications in the HPV
regulatory region in the tumor sample that were absent in the
benign samples from the same patients (Byrne et al., 1987;
DiLorenzo et al., 1992; Yuan et al., 2012). Thus, duplication
events in the papillomavirus genome may have an impact in
the infection phenotype, as they can deregulate the equilibria
between early and late genes expression, exacerbating viral repli-
cation as well as cellular duplication.
It could be claimed that intralesion viral diversity here
described may rather reﬂect an original infection by several
very-closely-related HPV16 genotypes. However, our current
understanding of HPV-associated disease suggests that individual
lesions are associated to individual infection events (Murray
et al., 1971; Quint et al., 2012). Instead, we propose here that
at least a fraction of such changes accumulated during infection
may arise from selection pressures associated to immune
response, underlying the high frequencies of above 40% for cer-
tain polymorphisms in a number of samples, such as CNA33,
CNA131 and CNA137. Regarding innate immune response, the
APOBEC3 internal mutators have been shown to target PV DNA,
introducing directional C > T changes (Vartanian et al., 2008;
Wang et al., 2014) The APOBEC3 locus has undergone a large
expansion in the human lineage (Munk et al., 2012), which
may partially account for the broad diversity of human PVs.
Regarding adaptive immune response, polymorphisms observed
in the E6 gene could be a result of an immune selective pressure.
Many linear epitopes have already been described in this region
(Dillner, 1990) and also could be related to the afﬁnity of the
interactions of E6 protein with E6-AP (Watts et al., 2002) and
p53 (Beckman et al., 1994). Polymorphisms in the E1 gene could
be related to the DNA binding domain and present in different
HPV16 sub-lineages, but do not affect the replication activity
(Kukimoto et al., 2013). Other humoral epitopes have also been
described in the E2 region (Dillner, 1990) and could drive
immune selection. Finally, an additional factor non-related to
immune response and that may have also fueled accumulation
of viral diversity in these lesions could be a cancer-related defect
in p53 functioning. Indeed, mutations ablating p53 activity are a
common feature of multiple human cancers, and underlie muta-
tion accumulation in different loci in advanced cancer stages.
However, HPV16 diversity in the condylomatous benign lesion
analyzed did not differ from the median of the viral diversity
detected in carcinomatous samples (0.387 vs 0.433, respectively).
The individual contribution of p53 mutations to intralesion viral
diversity remains thus unsolved.
Our results show that accumulation of HPV16 intralesion diver-
sity is a common feature in malignant and benign lesions induced
by this virus. We propose that such intra-host diversity is gener-
ated during the course of a chronic infection, either under muta-
tional pressures and drift, or also possibly fueled by immune
selection pressures, either innate – e.g. in response to APOBEC3
directional mutation – or adaptive – e.g. in response to humoral
or cellular directed responses. Since immune restrictions differ
between tissues, we anticipate that infections by the same viral
genotype may evolve to varying degrees of intralesion diversity.
Future larger studies of intralesion HPV genetic diversity, as well
50 C.M.d. Oliveira et al. / Infection, Genetics and Evolution 34 (2015) 44–51as, research on the natural history of the infection by HPVs will be
needed to monitor generation of viral diversity in asymptomatic,
productive, benign, premalignant and malignant infections.
Finally, the possible role of oncovirus intralesion diversity gener-
ated during chronic infections should be explored as a differential
factor for increased oncogenic potential.Acknowledgments
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